AXM Pharma Receives $1,000,000 Purchase Order From Jin Ming Shi Pharma

AXM Pharma, Inc. announced today that it received a $1,000,000 purchase order from Jin Ming Shi Pharma for the Company's line of Whisper feminine hygiene products for Shenzhen and its surrounding areas. The order is expected to ship in late March.

"Today marks the beginning of AXM Pharma's transition to a significant pharmaceutical manufacturing and distribution force in the Asian markets," said Madame Wang, Chairman of AXM Pharma. "This $1,000,000 purchase order is the first in a series of orders that are expected to come month after month as AXM Pharma ramps up production and becomes a full-fledged sales organization," she added.

The Whisper line includes Elegance Therapeutic Feminine Hygiene Wash, which is a feminine hygiene wash formulated with 8 herbal extracts and is pH balanced. The product is positioned as a therapeutic wash to relieve vaginal itch and vaginitis and to soothe any vaginal irritation that may be present. The feminine hygiene market segment in China is now valued at US$500 million. In Beijing alone, there are more than 1.5 million women in the initial target audience.

The Elegance Therapeutic Feminine Hygiene Wash target channel is pharmacies and supermarkets, whose growth is driven in part by the government's changes in healthcare financing, causing the consumer to purchase healthcare products in retail pharmacies; ending the practice of government subsidized dispensing of healthcare products in hospital outpatient wards.

AXM Pharma Inc., http://www.axmpharma.com, through its wholly owned subsidiary, Werke Pharmaceuticals, Inc., is the 100% owner of AXM Pharma Shenyang, Inc. ("AXM Shenyang"), a Wholly Foreign Owned Enterprise ("WFOE") under the laws of the People's Republic of China. AXM Shenyang is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang and its predecessor company Shenyang Tianwei Pharmaceutical Factory, Ltd. ("STPF"), has an operating history of approximately 10 years. AXM Shenyang historically has been a manufacturer and distributor of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. For additional information on AXM Pharma Inc, please visit http://www.iccinfo.com or call Investor Communications Company, LLC at 866 562 0134.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management.

Distributed by Market Wire